Dr. Reddy's Laboratories Ltd.

NSE: DRREDDY · Healthcare

₹1,221.00

as of 28 Sep 2026

AI verdict · 28 Sep 2026

Bearish 62% confidence

Q1 profit collapse (68.7% YoY) with unproven semaglutide remediation, bearish EMA stack, and weak volume outweigh speculative Qdenga upside.

Strongest bull point

Exclusive Qdenga vaccine distribution deal with H1 2027 launch and one-time ₹240 crore semaglutide charge create recovery opportunity if Q2 results show execution stabilization.

Strongest bear point

Confirmed 68.7% YoY profit decline, 5.6% revenue fall, US generics margin pressure, and bearish EMA stack (20<50<200) with 64% below-average volume signal sustained weakness.

Technical Forecast · next 10 trading days

Expected

₹1,213.78 -0.6%

Range

₹1,208.96 – ₹1,226.32

Technical Forecast Fundamental Debate

Free: 5 Forecasts and 5 Debates a month. Log in with your mobile number.

Every call on DRREDDY, misses included

Bearish 28 Sep 2026 → now Scores 28 Oct 2026

₹1,221.00 → ₹1,221.00 0.0%

Our accuracy

Every verdict and forecast here is dated and scored when it matures — right or wrong. The first scored results publish a month after launch.

How we score →

More Healthcare